Last updated on May 2020

A Study to Evaluate Long-term Safety in Subjects Who Have Participated in Other Luspatercept (ACE-536) Clinical Trials


Brief description of study

A Phase 3b, open-label, single-arm, rollover study to evaluate the long-term safety of luspatercept, to the following subjects:

  • Subjects receiving luspatercept on a parent protocol at the time of their transition to the rollover study, who tolerate the protocol-prescribed regimen in the parent trial and, in the opinion of the investigator, may derive clinical benefit in the opinion of the investigator from continuing treatment with luspatercept.
  • Placebo arm subjects from parent protocol (at the time of unblinding or in follow-up) crossing over to luspatercept treatment (provided subjects have met all requirements for entering the rollover study as per the parent protocol).
  • Subjects in the follow-up phase previously treated with luspatercept or placebo in the parent protocol will continue into long-term post-treatment follow-up in the rollover study until the follow-up commitments are met (unless they meet requirements as per parent protocol to cross-over to luspatercept treatment).

The study design is divided into the Transition Phase, Treatment Phase and Follow-up Phase. Subjects will enter transition phase and depending on their background will enter either the treatment phase or the Long-term Post-treatment Follow-up (LTPTFU) phase.

  • Transition Phase (Screening): up to 21 days prior to enrollment
  • Treatment Phase: For subjects in luspatercept treatment the dose and schedule of luspatercept in this study will be the same as the last dose and schedule in the parent luspatercept study. For placebo arm subjects from parent protocol (at the time of unblinding or in follow-up) crossing over to luspatercept treatment (provided subjects have met all requirements for entering the rollover study as per the parent protocol) will start at a luspatercept dose of 1.0 mg/kg every 3 weeks (Q3W). This does not apply to subjects that are in long-term follow-up from the parent protocol.
  • Follow-up Phase:
  • 42 Day Safety Follow-up Phase: subjects will be followed for 42 days after the last dose of luspatercept, for the assessment of safety-related parameters and adverse event (AE) reporting.
  • Long-term Post-treatment Follow-up (LTPTFU) Phase:

All subjects who are continuing in the LTPTFU Phase, will continue to be followed for 5 years from Dose 1 of the parent protocol, or 3 years of post-treatment from last dose of the parent protocol, whichever occurs later. Subjects will be followed every 6 months until death, withdrawal of consent, study termination, or until a subject is lost to follow-up. Subjects will also be monitored for progression to AML or any malignancies/pre- malignancies. New anticancer or disease related therapies should be collected at the same time schedule.

Subjects transitioning from a parent luspatercept study in post-treatment follow-up (safety or LTPTFU) will continue from the same equivalent point in this rollover study.

The rollover study will be terminated, and relevant subjects will discontinue from the study when all subjects fulfill 5 years from Dose 1 of the parent protocol, or 3 years of post-treatment from last dose of the parent protocol, whichever occurs later. The shift to commercial drug is an alternative way to stop the study.

Clinical Study Identifier: NCT04064060

Find a site near you

Start Over

Stanford Cancer Center

Stanford, CA United States
  Connect »

Moffitt Cancer Center

Tampa, FL United States
  Connect »

Karmanos Cancer Institute

Detroit, MI United States
  Connect »

Cleveland Clinic

Cleveland, OH United States
  Connect »

Mater Hospital Brisbane

South Brisbane, Australia
  Connect »

UZ Leuven

Leuven, Belgium
  Connect »

H pitaux de La Timone

Marseille Cedex 9, France
  Connect »

Centre Hospitalier Lyon Sud

Pierre Benite cedex, France
  Connect »

Hopital civil

Strasbourg, France
  Connect »

Marien Hospital

Dusseldorf, Germany
  Connect »

Queen Elizabeth Hospital

Kota Kinabalu, Malaysia
  Connect »

Kaohsiung Medical University Hospital

Kaohsiung, San Ming Dist., Taiwan
  Connect »

National Taiwan University Hospital

Taipei, Zhongzheng Dist., Taiwan
  Connect »

Aberdeen Royal Infirmary

Aberdeen, United Kingdom
  Connect »

Whittington Hospital

London, United Kingdom
  Connect »

Kings College Hospital

London, United Kingdom
  Connect »

Kings Mill Hospital

Sutton in Ashfield, United Kingdom
  Connect »

Hopitaux de La Timone

Marseille Cedex 9, France
  Connect »